Additional Information

Description

Imjudo (tremelimumab-actl) 20 mg/mL, 15 mL single-dose vial, is a human monoclonal antibody that functions as a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor. It is indicated for use in combination with other immunotherapeutic agents for the treatment of certain cancers, including unresectable hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC). By blocking CTLA-4, Imjudo enhances T-cell activation and proliferation, leading to increased immune response against tumor cells.

The mechanism of action involves binding to CTLA-4, preventing its interaction with CD80 and CD86 on antigen-presenting cells. This inhibition promotes T-cell-mediated antitumor activity, reducing immune suppression in the tumor microenvironment. The result is an enhanced and sustained immune response, facilitating tumor regression and improved disease control.

Common adverse effects include fatigue, diarrhea, rash, pruritus, nausea, and decreased appetite. Severe immune-mediated toxicities, such as pneumonitis, colitis, hepatitis, and endocrinopathies, may occur. Patients require regular monitoring for signs of immune-related adverse events, with corticosteroids or immunosuppressive therapy recommended for management of severe toxicities.